
Neoadjuvant PD-1 blockade with dostarlimab enabled high rates of organ preservation in early-stage dMMR solid tumors. In a phase 2 trial (n=117), 84 of 103 patients completing treatment achieved a clinical complete response, with 82 avoiding surgery. Recurrence-free survival at 2 years was 92%. Adverse events were mostly mild and reversible. This approach could transform curative treatment strategies across multiple dMMR tumor types.
Like
Save
Share